Summary
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
According to APO Research, The global PD-L1 Biomarker Testing market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for PD-L1 Biomarker Testing is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for PD-L1 Biomarker Testing is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for PD-L1 Biomarker Testing is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for PD-L1 Biomarker Testing is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of PD-L1 Biomarker Testing include Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent and Hengrui Medicine, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for PD-L1 Biomarker Testing, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of PD-L1 Biomarker Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for PD-L1 Biomarker Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PD-L1 Biomarker Testing revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global PD-L1 Biomarker Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for PD-L1 Biomarker Testing revenue, projected growth trends, production technology, application and end-user industry.
PD-L1 Biomarker Testing segment by Company
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
PD-L1 Biomarker Testing segment by Type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
PD-L1 Biomarker Testing segment by Application
Hospital
Diagnostic Center
Others
PD-L1 Biomarker Testing segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 Biomarker Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-L1 Biomarker Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 Biomarker Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of PD-L1 Biomarker Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of PD-L1 Biomarker Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-L1 Biomarker Testing revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 PD-L1 Biomarker Testing Market by Type
1.2.1 Global PD-L1 Biomarker Testing Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 PD-L1 (22C3)
1.2.3 PD-L1(28-8)
1.2.4 PD-L1 (SP142)
1.2.5 PD-L1 (SP263)
1.2.6 Other
1.3 PD-L1 Biomarker Testing Market by Application
1.3.1 Global PD-L1 Biomarker Testing Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Diagnostic Center
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 PD-L1 Biomarker Testing Market Dynamics
2.1 PD-L1 Biomarker Testing Industry Trends
2.2 PD-L1 Biomarker Testing Industry Drivers
2.3 PD-L1 Biomarker Testing Industry Opportunities and Challenges
2.4 PD-L1 Biomarker Testing Industry Restraints
3 Global Growth Perspective
3.1 Global PD-L1 Biomarker Testing Market Perspective (2019-2030)
3.2 Global PD-L1 Biomarker Testing Growth Trends by Region
3.2.1 Global PD-L1 Biomarker Testing Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global PD-L1 Biomarker Testing Market Size by Region (2019-2024)
3.2.3 Global PD-L1 Biomarker Testing Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global PD-L1 Biomarker Testing Revenue by Players
4.1.1 Global PD-L1 Biomarker Testing Revenue by Players (2019-2024)
4.1.2 Global PD-L1 Biomarker Testing Revenue Market Share by Players (2019-2024)
4.1.3 Global PD-L1 Biomarker Testing Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global PD-L1 Biomarker Testing Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global PD-L1 Biomarker Testing Key Players Headquarters & Area Served
4.4 Global PD-L1 Biomarker Testing Players, Product Type & Application
4.5 Global PD-L1 Biomarker Testing Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global PD-L1 Biomarker Testing Market CR5 and HHI
4.6.2 Global Top 5 and 10 PD-L1 Biomarker Testing Players Market Share by Revenue in 2023
4.6.3 2023 PD-L1 Biomarker Testing Tier 1, Tier 2, and Tier 3
5 PD-L1 Biomarker Testing Market Size by Type
5.1 Global PD-L1 Biomarker Testing Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global PD-L1 Biomarker Testing Revenue by Type (2019-2030)
5.3 Global PD-L1 Biomarker Testing Revenue Market Share by Type (2019-2030)
6 PD-L1 Biomarker Testing Market Size by Application
6.1 Global PD-L1 Biomarker Testing Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global PD-L1 Biomarker Testing Revenue by Application (2019-2030)
6.3 Global PD-L1 Biomarker Testing Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Agilent Technologies
7.1.1 Agilent Technologies Comapny Information
7.1.2 Agilent Technologies Business Overview
7.1.3 Agilent Technologies PD-L1 Biomarker Testing Revenue and Gross Margin (2019-2024)
7.1.4 Agilent Technologies PD-L1 Biomarker Testing Product Portfolio
7.1.5 Agilent Technologies Recent Developments
7.2 Roche
7.2.1 Roche Comapny Information
7.2.2 Roche Business Overview
7.2.3 Roche PD-L1 Biomarker Testing Revenue and Gross Margin (2019-2024)
7.2.4 Roche PD-L1 Biomarker Testing Product Portfolio
7.2.5 Roche Recent Developments
7.3 Merck
7.3.1 Merck Comapny Information
7.3.2 Merck Business Overview
7.3.3 Merck PD-L1 Biomarker Testing Revenue and Gross Margin (2019-2024)
7.3.4 Merck PD-L1 Biomarker Testing Product Portfolio
7.3.5 Merck Recent Developments
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Comapny Information
7.4.2 Bristol-Myers Squibb Business Overview
7.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue and Gross Margin (2019-2024)
7.4.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Product Portfolio
7.4.5 Bristol-Myers Squibb Recent Developments
7.5 AstraZeneca
7.5.1 AstraZeneca Comapny Information
7.5.2 AstraZeneca Business Overview
7.5.3 AstraZeneca PD-L1 Biomarker Testing Revenue and Gross Margin (2019-2024)
7.5.4 AstraZeneca PD-L1 Biomarker Testing Product Portfolio
7.5.5 AstraZeneca Recent Developments
7.6 Ono Pharmaceutical
7.6.1 Ono Pharmaceutical Comapny Information
7.6.2 Ono Pharmaceutical Business Overview
7.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue and Gross Margin (2019-2024)
7.6.4 Ono Pharmaceutical PD-L1 Biomarker Testing Product Portfolio
7.6.5 Ono Pharmaceutical Recent Developments
7.7 Regeneron
7.7.1 Regeneron Comapny Information
7.7.2 Regeneron Business Overview
7.7.3 Regeneron PD-L1 Biomarker Testing Revenue and Gross Margin (2019-2024)
7.7.4 Regeneron PD-L1 Biomarker Testing Product Portfolio
7.7.5 Regeneron Recent Developments
7.8 Innovent
7.8.1 Innovent Comapny Information
7.8.2 Innovent Business Overview
7.8.3 Innovent PD-L1 Biomarker Testing Revenue and Gross Margin (2019-2024)
7.8.4 Innovent PD-L1 Biomarker Testing Product Portfolio
7.8.5 Innovent Recent Developments
7.9 Hengrui Medicine
7.9.1 Hengrui Medicine Comapny Information
7.9.2 Hengrui Medicine Business Overview
7.9.3 Hengrui Medicine PD-L1 Biomarker Testing Revenue and Gross Margin (2019-2024)
7.9.4 Hengrui Medicine PD-L1 Biomarker Testing Product Portfolio
7.9.5 Hengrui Medicine Recent Developments
7.10 Junshi Biosciences
7.10.1 Junshi Biosciences Comapny Information
7.10.2 Junshi Biosciences Business Overview
7.10.3 Junshi Biosciences PD-L1 Biomarker Testing Revenue and Gross Margin (2019-2024)
7.10.4 Junshi Biosciences PD-L1 Biomarker Testing Product Portfolio
7.10.5 Junshi Biosciences Recent Developments
8 North America
8.1 North America PD-L1 Biomarker Testing Revenue (2019-2030)
8.2 North America PD-L1 Biomarker Testing Revenue by Type (2019-2030)
8.2.1 North America PD-L1 Biomarker Testing Revenue by Type (2019-2024)
8.2.2 North America PD-L1 Biomarker Testing Revenue by Type (2025-2030)
8.3 North America PD-L1 Biomarker Testing Revenue Share by Type (2019-2030)
8.4 North America PD-L1 Biomarker Testing Revenue by Application (2019-2030)
8.4.1 North America PD-L1 Biomarker Testing Revenue by Application (2019-2024)
8.4.2 North America PD-L1 Biomarker Testing Revenue by Application (2025-2030)
8.5 North America PD-L1 Biomarker Testing Revenue Share by Application (2019-2030)
8.6 North America PD-L1 Biomarker Testing Revenue by Country
8.6.1 North America PD-L1 Biomarker Testing Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America PD-L1 Biomarker Testing Revenue by Country (2019-2024)
8.6.3 North America PD-L1 Biomarker Testing Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe PD-L1 Biomarker Testing Revenue (2019-2030)
9.2 Europe PD-L1 Biomarker Testing Revenue by Type (2019-2030)
9.2.1 Europe PD-L1 Biomarker Testing Revenue by Type (2019-2024)
9.2.2 Europe PD-L1 Biomarker Testing Revenue by Type (2025-2030)
9.3 Europe PD-L1 Biomarker Testing Revenue Share by Type (2019-2030)
9.4 Europe PD-L1 Biomarker Testing Revenue by Application (2019-2030)
9.4.1 Europe PD-L1 Biomarker Testing Revenue by Application (2019-2024)
9.4.2 Europe PD-L1 Biomarker Testing Revenue by Application (2025-2030)
9.5 Europe PD-L1 Biomarker Testing Revenue Share by Application (2019-2030)
9.6 Europe PD-L1 Biomarker Testing Revenue by Country
9.6.1 Europe PD-L1 Biomarker Testing Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe PD-L1 Biomarker Testing Revenue by Country (2019-2024)
9.6.3 Europe PD-L1 Biomarker Testing Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China PD-L1 Biomarker Testing Revenue (2019-2030)
10.2 China PD-L1 Biomarker Testing Revenue by Type (2019-2030)
10.2.1 China PD-L1 Biomarker Testing Revenue by Type (2019-2024)
10.2.2 China PD-L1 Biomarker Testing Revenue by Type (2025-2030)
10.3 China PD-L1 Biomarker Testing Revenue Share by Type (2019-2030)
10.4 China PD-L1 Biomarker Testing Revenue by Application (2019-2030)
10.4.1 China PD-L1 Biomarker Testing Revenue by Application (2019-2024)
10.4.2 China PD-L1 Biomarker Testing Revenue by Application (2025-2030)
10.5 China PD-L1 Biomarker Testing Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia PD-L1 Biomarker Testing Revenue (2019-2030)
11.2 Asia PD-L1 Biomarker Testing Revenue by Type (2019-2030)
11.2.1 Asia PD-L1 Biomarker Testing Revenue by Type (2019-2024)
11.2.2 Asia PD-L1 Biomarker Testing Revenue by Type (2025-2030)
11.3 Asia PD-L1 Biomarker Testing Revenue Share by Type (2019-2030)
11.4 Asia PD-L1 Biomarker Testing Revenue by Application (2019-2030)
11.4.1 Asia PD-L1 Biomarker Testing Revenue by Application (2019-2024)
11.4.2 Asia PD-L1 Biomarker Testing Revenue by Application (2025-2030)
11.5 Asia PD-L1 Biomarker Testing Revenue Share by Application (2019-2030)
11.6 Asia PD-L1 Biomarker Testing Revenue by Country
11.6.1 Asia PD-L1 Biomarker Testing Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia PD-L1 Biomarker Testing Revenue by Country (2019-2024)
11.6.3 Asia PD-L1 Biomarker Testing Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA PD-L1 Biomarker Testing Revenue (2019-2030)
12.2 MEALA PD-L1 Biomarker Testing Revenue by Type (2019-2030)
12.2.1 MEALA PD-L1 Biomarker Testing Revenue by Type (2019-2024)
12.2.2 MEALA PD-L1 Biomarker Testing Revenue by Type (2025-2030)
12.3 MEALA PD-L1 Biomarker Testing Revenue Share by Type (2019-2030)
12.4 MEALA PD-L1 Biomarker Testing Revenue by Application (2019-2030)
12.4.1 MEALA PD-L1 Biomarker Testing Revenue by Application (2019-2024)
12.4.2 MEALA PD-L1 Biomarker Testing Revenue by Application (2025-2030)
12.5 MEALA PD-L1 Biomarker Testing Revenue Share by Application (2019-2030)
12.6 MEALA PD-L1 Biomarker Testing Revenue by Country
12.6.1 MEALA PD-L1 Biomarker Testing Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA PD-L1 Biomarker Testing Revenue by Country (2019-2024)
12.6.3 MEALA PD-L1 Biomarker Testing Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global PD-L1 Biomarker Testing Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. PD-L1 (22C3) Major Manufacturers
Table 2. PD-L1(28-8) Major Manufacturers
Table 3. PD-L1 (SP142) Major Manufacturers
Table 4. PD-L1 (SP263) Major Manufacturers
Table 5. Other Major Manufacturers
Table 6. Global PD-L1 Biomarker Testing Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 7. Hospital Major Manufacturers
Table 8. Diagnostic Center Major Manufacturers
Table 9. Others Major Manufacturers
Table 10. PD-L1 Biomarker Testing Industry Trends
Table 11. PD-L1 Biomarker Testing Industry Drivers
Table 12. PD-L1 Biomarker Testing Industry Opportunities and Challenges
Table 13. PD-L1 Biomarker Testing Industry Restraints
Table 14. Global PD-L1 Biomarker Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 15. Global PD-L1 Biomarker Testing Market Size by Region (2019-2024) & (US$ Million)
Table 16. Global PD-L1 Biomarker Testing Market Share by Region (2019-2024)
Table 17. Global PD-L1 Biomarker Testing Market Size by Region (2025-2030) & (US$ Million)
Table 18. Global PD-L1 Biomarker Testing Market Share by Region (2025-2030)
Table 19. Global PD-L1 Biomarker Testing Revenue by Players (US$ Million) & (2019-2024)
Table 20. Global PD-L1 Biomarker Testing Revenue Market Share by Players (2019-2024)
Table 21. Global PD-L1 Biomarker Testing Key Players Ranking, 2022 VS 2023 VS 2024
Table 22. Global PD-L1 Biomarker Testing Key Players Headquarters & Area Served
Table 23. Global PD-L1 Biomarker Testing Players, Product Type & Application
Table 24. Global PD-L1 Biomarker Testing Players Commercialization Time
Table 25. Global Players Market Concentration Ratio (CR5 and HHI)
Table 26. Global PD-L1 Biomarker Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 27. Global PD-L1 Biomarker Testing Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 28. Global PD-L1 Biomarker Testing Revenue by Type (2019-2024) & (US$ Million)
Table 29. Global PD-L1 Biomarker Testing Revenue by Type (2025-2030) & (US$ Million)
Table 30. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 31. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 32. Global PD-L1 Biomarker Testing Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 33. Global PD-L1 Biomarker Testing Revenue by Application (2019-2024) & (US$ Million)
Table 34. Global PD-L1 Biomarker Testing Revenue by Application (2025-2030) & (US$ Million)
Table 35. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 36. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 37. Agilent Technologies Company Information
Table 38. Agilent Technologies Business Overview
Table 39. Agilent Technologies PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 40. Agilent Technologies PD-L1 Biomarker Testing Product Portfolio
Table 41. Agilent Technologies Recent Development
Table 42. Roche Company Information
Table 43. Roche Business Overview
Table 44. Roche PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 45. Roche PD-L1 Biomarker Testing Product Portfolio
Table 46. Roche Recent Development
Table 47. Merck Company Information
Table 48. Merck Business Overview
Table 49. Merck PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 50. Merck PD-L1 Biomarker Testing Product Portfolio
Table 51. Merck Recent Development
Table 52. Bristol-Myers Squibb Company Information
Table 53. Bristol-Myers Squibb Business Overview
Table 54. Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 55. Bristol-Myers Squibb PD-L1 Biomarker Testing Product Portfolio
Table 56. Bristol-Myers Squibb Recent Development
Table 57. AstraZeneca Company Information
Table 58. AstraZeneca Business Overview
Table 59. AstraZeneca PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 60. AstraZeneca PD-L1 Biomarker Testing Product Portfolio
Table 61. AstraZeneca Recent Development
Table 62. Ono Pharmaceutical Company Information
Table 63. Ono Pharmaceutical Business Overview
Table 64. Ono Pharmaceutical PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 65. Ono Pharmaceutical PD-L1 Biomarker Testing Product Portfolio
Table 66. Ono Pharmaceutical Recent Development
Table 67. Regeneron Company Information
Table 68. Regeneron Business Overview
Table 69. Regeneron PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 70. Regeneron PD-L1 Biomarker Testing Product Portfolio
Table 71. Regeneron Recent Development
Table 72. Innovent Company Information
Table 73. Innovent Business Overview
Table 74. Innovent PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 75. Innovent PD-L1 Biomarker Testing Product Portfolio
Table 76. Innovent Recent Development
Table 77. Hengrui Medicine Company Information
Table 78. Hengrui Medicine Business Overview
Table 79. Hengrui Medicine PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 80. Hengrui Medicine PD-L1 Biomarker Testing Product Portfolio
Table 81. Hengrui Medicine Recent Development
Table 82. Junshi Biosciences Company Information
Table 83. Junshi Biosciences Business Overview
Table 84. Junshi Biosciences PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 85. Junshi Biosciences PD-L1 Biomarker Testing Product Portfolio
Table 86. Junshi Biosciences Recent Development
Table 87. North America PD-L1 Biomarker Testing Revenue by Type (2019-2024) & (US$ Million)
Table 88. North America PD-L1 Biomarker Testing Revenue by Application (2019-2024) & (US$ Million)
Table 89. North America PD-L1 Biomarker Testing Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 90. North America PD-L1 Biomarker Testing Revenue by Country (2019-2024) & (US$ Million)
Table 91. North America PD-L1 Biomarker Testing Revenue by Country (2025-2030) & (US$ Million)
Table 92. Europe PD-L1 Biomarker Testing Revenue by Type (2019-2024) & (US$ Million)
Table 93. Europe PD-L1 Biomarker Testing Revenue by Application (2019-2024) & (US$ Million)
Table 94. Europe PD-L1 Biomarker Testing Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 95. Europe PD-L1 Biomarker Testing Revenue by Country (2019-2024) & (US$ Million)
Table 96. Europe PD-L1 Biomarker Testing Revenue by Country (2025-2030) & (US$ Million)
Table 97. China PD-L1 Biomarker Testing Revenue by Type (2019-2024) & (US$ Million)
Table 98. China PD-L1 Biomarker Testing Revenue by Application (2019-2024) & (US$ Million)
Table 99. Asia PD-L1 Biomarker Testing Revenue by Type (2019-2024) & (US$ Million)
Table 100. Asia PD-L1 Biomarker Testing Revenue by Application (2019-2024) & (US$ Million)
Table 101. Asia PD-L1 Biomarker Testing Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 102. Asia PD-L1 Biomarker Testing Revenue by Country (2019-2024) & (US$ Million)
Table 103. Asia PD-L1 Biomarker Testing Revenue by Country (2025-2030) & (US$ Million)
Table 104. MEALA PD-L1 Biomarker Testing Revenue by Type (2019-2024) & (US$ Million)
Table 105. MEALA PD-L1 Biomarker Testing Revenue by Application (2019-2024) & (US$ Million)
Table 106. MEALA PD-L1 Biomarker Testing Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 107. MEALA PD-L1 Biomarker Testing Revenue by Country (2019-2024) & (US$ Million)
Table 108. MEALA PD-L1 Biomarker Testing Revenue by Country (2025-2030) & (US$ Million)
Table 109. Research Programs/Design for This Report
Table 110. Authors List of This Report
Table 111. Secondary Sources
Table 112. Primary Sources
List of Figures
Figure 1. PD-L1 Biomarker Testing Product Picture
Figure 2. Global PD-L1 Biomarker Testing Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global PD-L1 Biomarker Testing Market Size Share 2019 VS 2023 VS 2030
Figure 4. PD-L1 (22C3) Picture
Figure 5. PD-L1(28-8) Picture
Figure 6. PD-L1 (SP142) Picture
Figure 7. PD-L1 (SP263) Picture
Figure 8. Other Picture
Figure 9. Global PD-L1 Biomarker Testing Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 10. Global PD-L1 Biomarker Testing Market Size Share 2019 VS 2023 VS 2030
Figure 11. Hospital Picture
Figure 12. Diagnostic Center Picture
Figure 13. Others Picture
Figure 14. Global PD-L1 Biomarker Testing Market Size (US$ Million) & (2019-2030)
Figure 15. Global PD-L1 Biomarker Testing Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global PD-L1 Biomarker Testing Market Share by Region: 2019 VS 2023 VS 2030
Figure 17. Global PD-L1 Biomarker Testing Players Revenue Share Top 10 and Top 5 in 2023
Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 19. Global PD-L1 Biomarker Testing Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 20. Global PD-L1 Biomarker Testing Revenue Market Share 2019 VS 2023 VS 2030
Figure 21. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2019-2030)
Figure 22. Global PD-L1 Biomarker Testing Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 24. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2019-2030)
Figure 25. North America PD-L1 Biomarker Testing Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 26. North America PD-L1 Biomarker Testing Revenue by Type (2025-2030) & (US$ Million)
Figure 27. North America PD-L1 Biomarker Testing Revenue Share by Type (2019-2030)
Figure 28. North America PD-L1 Biomarker Testing Revenue by Application (2025-2030) & (US$ Million)
Figure 29. North America PD-L1 Biomarker Testing Revenue Share by Application (2019-2030)
Figure 30. North America PD-L1 Biomarker Testing Revenue Share by Country (2019-2030)
Figure 31. United States PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 32. Canada PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 33. Europe PD-L1 Biomarker Testing Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 34. Europe PD-L1 Biomarker Testing Revenue by Type (2025-2030) & (US$ Million)
Figure 35. Europe PD-L1 Biomarker Testing Revenue Share by Type (2019-2030)
Figure 36. Europe PD-L1 Biomarker Testing Revenue by Application (2025-2030) & (US$ Million)
Figure 37. Europe PD-L1 Biomarker Testing Revenue Share by Application (2019-2030)
Figure 38. Europe PD-L1 Biomarker Testing Revenue Share by Country (2019-2030)
Figure 39. Germany PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. France PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. U.K. PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Italy PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Russia PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. Nordic Countries PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 45. China PD-L1 Biomarker Testing Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 46. China PD-L1 Biomarker Testing Revenue by Type (2025-2030) & (US$ Million)
Figure 47. China PD-L1 Biomarker Testing Revenue Share by Type (2019-2030)
Figure 48. China PD-L1 Biomarker Testing Revenue by Application (2025-2030) & (US$ Million)
Figure 49. China PD-L1 Biomarker Testing Revenue Share by Application (2019-2030)
Figure 50. Asia PD-L1 Biomarker Testing Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 51. Asia PD-L1 Biomarker Testing Revenue by Type (2025-2030) & (US$ Million)
Figure 52. Asia PD-L1 Biomarker Testing Revenue Share by Type (2019-2030)
Figure 53. Asia PD-L1 Biomarker Testing Revenue by Application (2025-2030) & (US$ Million)
Figure 54. Asia PD-L1 Biomarker Testing Revenue Share by Application (2019-2030)
Figure 55. Asia PD-L1 Biomarker Testing Revenue Share by Country (2019-2030)
Figure 56. Japan PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. South Korea PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. India PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. Australia PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. China Taiwan PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. Southeast Asia PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 62. MEALA PD-L1 Biomarker Testing Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 63. MEALA PD-L1 Biomarker Testing Revenue by Type (2025-2030) & (US$ Million)
Figure 64. MEALA PD-L1 Biomarker Testing Revenue Share by Type (2019-2030)
Figure 65. MEALA PD-L1 Biomarker Testing Revenue by Application (2025-2030) & (US$ Million)
Figure 66. MEALA PD-L1 Biomarker Testing Revenue Share by Application (2019-2030)
Figure 67. MEALA PD-L1 Biomarker Testing Revenue Share by Country (2019-2030)
Figure 68. Mexico PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. South Korea PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Brazil PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Israel PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Argentina PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Colombia PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Turkey PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. Saudi Arabia PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. UAE PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 77. Years Considered
Figure 78. Research Process
Figure 79. Key Executives Interviewed
